Table 1

Baseline demographic features of the patients with advanced gastroesophageal adenocarcinoma

Best supportive care (BSC)Palliative chemotherapyP value
n = 75n = 52
Age (median, years±range)80 (54–95)68 (36–83)0.019
Sex0.56
 Male50 (67%)38 (73%)
 Female25 (33%)14 (27%)
ECOG PS<0.0001
 0/130 (40%)44 (85%)
 222 (29%)5 (10%)
 >222 (29%)1 (2%)
 Unknown1 (1%)2 (4%)
TNM stage
 Stage 1/216 (21%)0 (0%)0.0004
 Stage 316 (21%)9 (17%)
 Stage 4a10 (13%)6 (12%)
 Stage 4b29 (39%)37 (71%)
 Unknown4 (5%)0 (0%)
Stent inserted28 (37%)20 (38%)0.72
Albumin (g/dL)32 (25–36)37 (32–39)0.034
Chemotherapy regime
 EOX28 (54%)
 OX14 (27%)
 EOF1 (2%)
 ECX1 (2%)
 CX2 (4%)
 CX-H6 (12%)
  • The TNM Classification of Malignant Tumours (TNM) is a globally recognised standard for classifying the extent of spread of cancer. For this study, TNM edition 8 was used.

  • CX, cisplatin/capecitabine; CX-H, cisplatin/capecitabine/trastuzumab; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ECX, epirubicin/cisplatin/capecitabine; EOF, epirubicin/oxaliplatin/5-fluorouracil; EOX, epirubicin/oxaliplatin/capecitabine; OX, oxaliplatin/capecitabine.